SEHK:460Pharmaceuticals
Assessing Sihuan Pharmaceutical Holdings Group’s Valuation After Earnings Turnaround And Positive Bireociclib Phase 3 Results
Sihuan Pharmaceutical Holdings Group (SEHK:460) has drawn investor attention after reporting full year 2025 earnings, showing CNY 2,618.01 million in sales and CNY 179.7 million in net income, alongside positive final Phase 3 data for Bireociclib.
See our latest analysis for Sihuan Pharmaceutical Holdings Group.
The earnings turnaround and Bireociclib news sit alongside a 17.9% 90 day share price return and a 121.2% 1 year total shareholder return. However, the 5 year total shareholder return...